JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3604 Mibefradil

Target: Voltage-gated Calcium Channels (CaV)

Summary: Calcium channel blocker

≥49.6 mg/mL
A3662 NNC 55-0396

Target: Voltage-gated Calcium Channels (CaV)

Summary: T-type calcium channel blocker

Soluble to 25 mM in sterile water
B1989 Nisoldipine

Target: Voltage-gated Calcium Channels (CaV)

Summary: calcium channel blocker
B1867 Verapamil HCl
1 Citation

Target: Voltage-gated Calcium Channels (CaV)

Summary: L-type calcium channel blocker

≥14.45 mg/mL
B2278 Ibutilide Fumarate

Target: Voltage-gated Potassium (KV) Channels|Voltage-gated Calcium Channels (CaV)|sodium channel

Summary: Class III antiarrhythmic agent

≥25.6 mg/mL
B1393 Nitrendipine

Target: Voltage-gated Calcium Channels (CaV)

Summary: Calcium channel blocker

insoluble in H2O; ≥13.7 mg/mL
B1410 Amlodipine

Target: Voltage-gated Calcium Channels (CaV)

Summary: Calcium channel blocker

insoluble in H2O; ≥17.7 mg/mL
B2268 Amiloride HCl dihydrate

Target: Voltage-gated Sodium (NaV) Channels|Voltage-gated Calcium Channels (CaV)|Urokinases

Summary: potent epithelial sodium channel (ENaC) blocker

insoluble in EtOH; insoluble in H2O; ≥14.05 mg/mL
B5351 SNX 482

Target: Voltage-gated Calcium Channels (CaV)

Summary: voltage-dependent R-type CaV2.3 calcium channel blocker

Soluble in H2O
A5354 Zonisamide

Target: Voltage-gated Sodium (NaV) Channels|Voltage-gated Calcium Channels (CaV)|Carbonic Anhydrases|Calcium-Activated Potassium (KCa) Channels

Summary: Antiepileptic with anticonvulsant and mechanistic effect

insoluble in H2O; ≥8.35 mg/mL